Bristol-Myers Squibb gives full responsibility for Erbitux in Japan to Merck

13 February 2015

German pharmaceuticals and chemicals major Merck KGaA (MRK: DE) is to end the co-promotion of Erbitux (cetuximab) in Japan with US pharma major Bristol-Myers Squibb (NYSE: BMY).

The responsibility for the promotion of Erbitux will be transferred to Merck in Japan as of May 1, 2015, giving it greater presence in the region, and the company has already positioned Japan as its regional research and development hub for North East Asia.

Belen Garijo, chief executive of health care at Merck, said: "Expanding our oncology presence in Japan is of strategic importance to achieve our long term ambition to become a leading global player in oncology and immuno-oncology.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK